IBR2
Based on 7 publication(s) in Google Scholar
IBR2 is a potent and specific RAD51 inhibitor and inhibits RAD51-mediated DNA double-strand break repair. IBR2 disrupts RAD51 multimerization, accelerates proteasome-mediated RAD51 protein degradation, inhibits cancer cell growth and induces apoptosis.
For research use only. We do not sell to patients.
- Purity: 98.24%
- CAS No.: 313526-24-8
- Formula: C24H20N2O2S
- Molecular Weight:400.49
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Anti-Breast Cancer Compound Library
HY-L074
-
Targeted Diversity Library
HY-L099
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) IBR2
More- Sci Bull. 2025 Aug 25:S2095-9273(25)00865-5. [Abstract]
- Reprod Biol Endocrinol. 2025 Jul 3;23(1):93. [Abstract]
- J Virol. 2023 Dec 21;97(12):e0173723. [Abstract]
- Theriogenology. 2026 Jun 24:265:118052. [Abstract]
- Biomed Rep. 2023 Feb 24;18(4):28. [Abstract]
- Patent. US20250049807A1.
- CUNY Hunter College. 2020 Sep.
Biological Activity
RAD51[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDA-MB-468 | IC50 |
14.8 μM
Compound: IBR2 (rac)
|
Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 4 days by XTT assay
Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 4 days by XTT assay
|
[PMID: 25874343] |
IBR2 shows interesting RAD51 inhibition activities. RAD51 is rapidly degraded in IBR2-treated cancer cells, and the homologous recombination repair is impaired, subsequently leading to cell death. The IC50 values of the original IBR2 are in the range of 12-20 μM for most tested cancer cell lines. IBR2 can inhibit the growth of triple-negative human breast cancer cell line MBA-MD-468 with an IC50 of 14.8 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 313526-24-8
-
Appearance Solid
-
Molecular Weight 400.49
-
Formula C24H20N2O2S
-
Color Off-white to pink
-
SMILES
O=S(N1C(C2=CNC3=C2C=CC=C3)C4=C(C=CC=C4)C=C1)(CC5=CC=CC=C5)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Sci Bull
Insufficient telomeric DNA damage response promotes chromosomal instability in aged oocytes. [Abstract]2025 Aug 25:S2095-9273(25)00865-5. PMID: 40930920 -
Reprod Biol Endocrinol
Rapamycin reduces DNA damage of in vitro matured oocytes by promoting Rad51-mediated homologous recombination. [Abstract]2025 Jul 3;23(1):93. PMID: 40611176 -
J Virol
SARS-CoV-2 exploits cellular RAD51 to promote viral propagation: implication of RAD51 inhibitor as a potential drug candidate against COVID-19. [Abstract]2023 Dec 21;97(12):e0173723. PMID: 38051260 -
Theriogenology
Farrerol improves the maturation quality of porcine oocytes derived from small follicles associated with RAD51-related DNA repair responses. [Abstract]2026 Jun 24:265:118052. PMID: 42379065 -
Biomed Rep
DNA‑PKcs phosphorylation specific inhibitor, NU7441, enhances the radiosensitivity of clinically relevant radioresistant oral squamous cell carcinoma cells. [Abstract]2023 Feb 24;18(4):28. PMID: 36926187 -
-
Solvent & Solubility
DMSO : ≥ 100 mg/mL (249.69 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.24 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Human breast cancer cell lines MCF7, MDA-MB-231, MDA-MB-361, MDA-MB-435, MDA-MB468, Hs578-T, human osteosarcoma cell line U20S, human glioblastoma cell line T98G and human cervical adenocarcinoma cell line HeLa are used. Standard XTT assays with a four-day drug treatment procedure are performed to measure the dose dependent cytotoxicity of IBR analogs in cultured cells. In brief, cells are plated on 96-well dishes one day before the drug treatment, followed by drug (e.g., IBR2) treatment on day 2 and XTT assay on day 6 after drug addition by using a commercial cell proliferation kit . Triplicate sets are measured and compiled for final data presentation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Jiewen Zhu, et al. A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia. EMBO Mol Med. 2013 Mar;5(3):353-65. [Content Brief]
[2]. Zhu J, et al. Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors. Eur J Med Chem. 2015;96:196-208. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4969 mL | 12.4847 mL | 24.9694 mL | 62.4235 mL |
| 5 mM | 0.4994 mL | 2.4969 mL | 4.9939 mL | 12.4847 mL | |
| 10 mM | 0.2497 mL | 1.2485 mL | 2.4969 mL | 6.2424 mL | |
| 15 mM | 0.1665 mL | 0.8323 mL | 1.6646 mL | 4.1616 mL | |
| 20 mM | 0.1248 mL | 0.6242 mL | 1.2485 mL | 3.1212 mL | |
| 25 mM | 0.0999 mL | 0.4994 mL | 0.9988 mL | 2.4969 mL | |
| 30 mM | 0.0832 mL | 0.4162 mL | 0.8323 mL | 2.0808 mL | |
| 40 mM | 0.0624 mL | 0.3121 mL | 0.6242 mL | 1.5606 mL | |
| 50 mM | 0.0499 mL | 0.2497 mL | 0.4994 mL | 1.2485 mL | |
| 60 mM | 0.0416 mL | 0.2081 mL | 0.4162 mL | 1.0404 mL | |
| 80 mM | 0.0312 mL | 0.1561 mL | 0.3121 mL | 0.7803 mL | |
| 100 mM | 0.0250 mL | 0.1248 mL | 0.2497 mL | 0.6242 mL |
IBR2 Related Classifications
HY-103710 Related Classifications
Powered by Bioz